Medicare ESRD Payment Should Account For Epogen Price Increase, Dialysis Centers Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Dialysis centers write to CMS saying that upcoming Medicare payment cuts for end-stage renal disease treatment, combined with a 5% Epogen price increase, will put “additional pressure on already thin Medicare margins.”